World's Best Scientists 2026 revealed!
Marco M. Gottardis

Marco M. Gottardis

D-Index & Metrics

Biology and Biochemistry

D-Index
57
Citations
11313
World Ranking
13872
National Ranking
5865

Overview

Marco M. Gottardis is affiliated with NKGen Biotech Inc in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a specific focus on Pulmonary and Respiratory Medicine, Molecular Biology, Immunology, Oncology, and Cancer Research.

The main topics addressed in their work include Prostate Cancer Treatment and Research, Ubiquitin and proteasome pathways, Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers, Cancer, Lipids, and Metabolism, Protein Degradation and Inhibitors, and Hormonal and reproductive studies.

Notable recent publications by Marco M. Gottardis include the following:

  • Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors, 2020, Cell chemical biology
  • Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer, 2021, Prostate Cancer and Prostatic Diseases
  • Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC), 2021, Journal of Medicinal Chemistry
  • Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor), 2023, Journal for ImmunoTherapy of Cancer
  • The discovery of BMS-737 as a potent, CYP17 lyase-selective inhibitor for the treatment of castration-resistant prostate cancer, 2022, Bioorganic & Medicinal Chemistry Letters

Frequent coauthors collaborating with Marco M. Gottardis include Jonathan R. Branch, Gilles Bignan, Ian Hickson, James R. Bischoff, and Brent Rupnow.

The scientist has published in several venues with multiple contributions to Cell chemical biology, Prostate Cancer and Prostatic Diseases, Journal of Medicinal Chemistry, Journal for ImmunoTherapy of Cancer, and Cancer Research Communications.

Best Publications

  • Phosphorylated Insulin-Like Growth Factor-I/Insulin Receptor Is Present in All Breast Cancer Subtypes and Is Related to Poor Survival

    Jennifer H. Law;Golareh Habibi;Kaiji Hu;Hamid Masoudi

  • Effect of cadmium on estrogen receptor levels and estrogen-induced responses in human breast cancer cells.

    P. Garcia-Morales;M. Saceda;N. Kenney;N. Kim

  • BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR

    Joan M. Carboni;Mark Wittman;Zheng Yang;Francis Lee

  • Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes.

    Ruslan Novosyadlyy;Danielle E. Lann;Archana Vijayakumar;Anne Rowzee;Anne Rowzee

  • Decreased Egr‐1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation

    Ruo-Pan Huang;Yan Fan;Ian De Belle;Christina Niemeyer

  • Constitutively Active Type I Insulin-Like Growth Factor Receptor Causes Transformation and Xenograft Growth of Immortalized Mammary Epithelial Cells and Is Accompanied by an Epithelial-to-Mesenchymal Transition Mediated by NF-κB and Snail

    Hyun Jung Kim;Beate C. Litzenburger;Xiaojiang Cui;David A. Delgado

  • Chemoprevention of Mammary Carcinoma by LGD1069 (Targretin): An RXR-selective Ligand

    Marco M. Gottardis;Eric D. Bischoff;Michael A. Shirley;Murriel A. Wagoner

  • In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.

    Paul Haluska;Joan M. Carboni;David A. Loegering;Francis Y. Lee

  • Castration-resistant prostate cancer: locking up the molecular escape routes.

    Ricardo M. Attar;Chris H. Takimoto;Marco M. Gottardis

  • Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor

    Joan M. Carboni;Adrian V. Lee;Darryl L. Hadsell;Bruce R. Rowley

  • Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen.

    Marco M. Gottardis;Simon P. Robinson;V.Craig Jordan

  • The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors.

    Fei Huang;Ann Greer;Warren Hurlburt;Xia Han

  • Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma.

    Eric D. Bischoff;Marco M. Gottardis;Thomas E. Moon;Richard A. Heyman

  • Synergistic methods and compositions for treating cancer

    Joan M. Carboni;Warren W. Hurlburt;Marco M. Gottardis

  • Circumventing Tamoxifen Resistance in Breast Cancers Using Antiestrogens That Induce Unique Conformational Changes in the Estrogen Receptor

    Caroline E. Connor;John D. Norris;Gloria Broadwater;Timothy M. Willson

  • High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling

    Hind Medyouf;Samuel Gusscott;Hongfang Wang;Jen Chieh Tseng

  • Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity.

    Mark Wittman;Joan Carboni;Ricardo Attar;Balu Balasubramanian

  • The androgen receptor can signal through Wnt/β-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens

    Liang Schweizer;Cheryl A Rizzo;Thomas E Spires;J Suso Platero

  • Drug safety is a barrier to the discovery and development of new androgen receptor antagonists

    William R. Foster;Bruce D. Car;Hong Shi;Paul C. Levesque

  • Estrogen stimulation and tamoxifen inhibition of leiomyoma cell growth in vitro and in vivo

    S R Howe;M M Gottardis;J I Everitt;C Walker

Frequent Co-Authors

George L. Trainor
George L. Trainor Bristol-Myers Squibb (Germany)
Michael Pollak
Michael Pollak McGill University
Gary E. Gallick
Gary E. Gallick The University of Texas MD Anderson Cancer Center
Cheryl L. Walker
Cheryl L. Walker Baylor College of Medicine
John T. Hunt
John T. Hunt Bristol-Myers Squibb (Germany)
Hinrich Gronemeyer
Hinrich Gronemeyer Institute of Genetics and Molecular and Cellular Biology
Christopher J. Logothetis
Christopher J. Logothetis The University of Texas MD Anderson Cancer Center
Michael T. Lewis
Michael T. Lewis Baylor College of Medicine

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you are interested in advancing your career in Biology or Biochemistry, there are several flexible online pathways to consider. Many healthcare and science-related fields now offer accelerated and accessible online degree options, tailored to meet the needs of busy professionals and students.

For those looking to specialize in mental health nursing, the fastest pmhnp program options can help you quickly gain qualifications as a Psychiatric Mental Health Nurse Practitioner. Alternatively, those in nursing may choose the 12-month fnp program online to become a Family Nurse Practitioner in just one year.

If nutrition and wellness are your interests, explore an accelerated nutrition degree online to fast-track your entry into the dietetics field. Current registered nurses seeking advancement can benefit from the easiest rn to bsn online program, designed for ease of learning and speed of completion.

These diverse online programs offer a blend of flexibility and speed, making it easier than ever to pursue specialized careers linked to Biology, Biochemistry, and the health sciences.

Best Scientists Citing Marco M. Gottardis

Trending Scientists